Key result
Leadless pacing emerges as a potential cardiac pacing option for young patients.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Requires prospective data before routine use in young patients; leaves open the role of leadless pacing in this demographic.
R. K. reports consultancy fees and research grants from Abbott, Boston Scientific, Medtronic, and Cairdac and has stock options from AtaCor Medical Inc. F. T. received consulting honoraria from Abbott and Boston Scientific.
No takes yet. Share an insight, caveat, or question.
Breeman et al. (2022) studied this question. Leadless pacing is being evaluated as a potential cardiac pacing option for young patients.
Synapse has enriched 10 related papers. Consider them for comparative context: